Study Detail

Phase III trial of inhaled anti-viral (SNG001) for SARS-CoV-2

A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19

Status: Open

Type: Interventional

Funder: Synairgen Research Limited

Sponsor: Synairgen Research Limited

CI: Professor Tom Wilkinson

IRAS-Number: 290965

CPMS-ID: 47416

Approval Date: 14 October 2020

Study URL:

Back to listing